Radiolabeled peptides hold promise for diagnosis and therapy of cancer as well as for early monitoring of therapy outcomes,
patient stratification, etc. This manuscript focuses on the development of peptides labeled with 18F, 64Cu, 68Ga and other positron-emitting
radionuclides for PET imaging. The major techniques for radionuclide incorporation are briefly discussed. Then, examples of positronemitting
peptides targeting somatostatin receptors, integrins, gastrin-releasing peptide receptors, vasointestinal peptide receptors,
melanocortin 1 receptors and others are reviewed.
Keywords: α-MSH, Bombesin, Octreotide analogs, Peptide receptors, PET, RGD, VIP, SOMATOSTATIN, NEUROENDOCRINE TUMORS, INTEGRIN, ANGIOGENESIS
Rights & PermissionsPrintExport